checkAd

    Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C  225  0 Kommentare Preclinical Data Published - Seite 3

    Investor Contact
    Mark Joinnides
    ir@vaxxinity.com

    Press Contact
    Jon Yu
    media@vaxxinity.com

    i World Health Organization. (2021, July). Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

    ii Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664

    Lesen Sie auch

    iii Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. doi:10.1056/NEJMoa1801174



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C Preclinical Data Published - Seite 3 Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of VXX-401 is ongoing, with topline results expected …